The DOI matches its Crossref record.
The consent form as a possible cause of side effects
Abstract
In a multicenter trial of aspirin or sulfinpyrazone in the treatment of unstable angina, we examined the possible importance to the outcome of mentioning potential side effects in the consent form. Inclusion, in two of the three centers, of a statement outlining possible gastrointestinal side effects resulted in a sixfold increase (P less than 0.001) in the number of subjects in these centers withdrawing from the study because of subjective, minor gastrointestinal symptoms. Major gastrointestinal complications such as peptic ulcer or bleeding as diagnosed by study physicians were similar in the three centers. Furthermore, no patient discontinued therapy because of subjective, nongastrointestinal side effects. Post hoc analysis suggests that the inclusion of gastrointestinal side effects in the consent form may have increased the likelihood of patients attributing gastrointestinal symptoms to drug therapy, leading to subsequent withdrawal from the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Barsky, A. J., & Borus, J. F. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-11-199906010-00016 · Cited by 950
Barriers to Participation in Randomised Controlled Trials
Ross, S., Grant, A., Counsell, C., Gillespie, W., Russell, I., & Prescott, R. (1999) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00141-9 · Cited by 907
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
The double-blind, randomized, placebo-controlled trial
Kaptchuk, T. J. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00347-4 · Cited by 595
Sham device v inert pill: randomised controlled trial of two placebo treatments
Kaptchuk, T. J., Stason, W. B., Davis, R. B., Legedza, A. R. T., Schnyer, R. N., Kerr, C. E., Stone, D. A., Nam, B. H., Kirsch, I., & Goldman, R. H. (2006) · BMJ · doi:10.1136/bmj.38726.603310.55 · Cited by 532
Partnerships with Patients: The Pros and Cons of Shared Clinical Decision-Making
Coulter, A. (1997) · Journal of Health Services Research & Policy · doi:10.1177/135581969700200209 · Cited by 487
The Nocebo Effect and Its Relevance for Clinical Practice
Colloca, L., & Miller, F. G. (2011) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3182294a50 · Cited by 419
Factors that limit the quality, number and progress of randomised controlled trials
Prescott, Counsell, Gillespie, Grant, Russell, Kiauka, Colthart, Ross, Shepherd, & Russell (1999) · Health Technology Assessment · doi:10.3310/hta3200 · Cited by 390
Dworkin, R. H., Turk, D. C., Peirce-Sandner, S., Baron, R., Bellamy, N., Burke, L. B., Chappell, A., Chartier, K., Cleeland, C. S., Costello, A., et al. (2010) · Pain · doi:10.1016/j.pain.2010.02.018 · Cited by 381
Crow, Gage, Hampson, Hart, Kimber, & Thomas (1999) · Health Technology Assessment · doi:10.3310/hta3030 · Cited by 358
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Petrie, K. J., & Rief, W. (2019) · Annual Review of Psychology · doi:10.1146/annurev-psych-010418-102907 · Cited by 309
“A longitudinal study of patients with rheumatoid arthritis found that patients with more concerns about their medication at baseline were more likely to report side effects six months after beginning treatment (Nestoriuc et al. 2010).”
BackgroundWells, R. E., & Kaptchuk, T. J. (2012) · The American Journal of Bioethics · doi:10.1080/15265161.2011.652798 · Cited by 271
A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect
Kong, J., Gollub, R. L., Polich, G., Kirsch, I., LaViolette, P., Vangel, M., Rosen, B., & Kaptchuk, T. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2944-08.2008 · Cited by 263
“, 2002), adverse events in clinical trials and medical care (Myers et al., 1987; Roscoe et al., 2000; Reuter et al., 2003; Kaptchuk et al., 2006), and public health “mass psychogenic illness” outbreaks (Jones et al.”
A systematic review of factors that contribute to nocebo effects
Webster, R. K., Weinman, J., & Rubin, G. J. (2016) · Health Psychology · doi:10.1037/hea0000416 · Cited by 172
Learning one’s genetic risk changes physiology independent of actual genetic risk
Turnwald, B. P., Goyer, J. P., Boles, D. Z., Silder, A., Delp, S. L., & Crum, A. J. (2018) · Nature Human Behaviour · doi:10.1038/s41562-018-0483-4 · Cited by 142
Faasse, K., Gamble, G., Cundy, T., & Petrie, K. J. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001607 · Cited by 83
Wendt, L., Albring, A., Benson, S., Engler, H., Engler, A., Hinney, A., Rief, W., Witzke, O., & Schedlowski, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107665 · Cited by 47
(2019) · doi:10.32872/cpe.v1i1.29642 · Cited by 24
Metadata
- Authors
- Myers, M. G., Cairns, J. A., & Singer, J.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1987-09
- Volume
- 42
- Issue
- 3
- Pages
- 250-253
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1966754527
- Cited by
- 219
- References
- 0
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.